BioPharmSignal logoBioPharmSignal

Biotech News

Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia

Minerva Neuroscience (NERV)Minerva NeuroscienceCompany update

Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it will host an in-person and virtual event in New York on Thursday, November 12, 2026, at 10:00 AM ET featuring several key opinion leaders and company management focused on the opportunity for roluperidone in treating the negative symptoms of schizophrenia. For more details and to register for the event, click here .

Related news

NERVMinerva Neuroscience2026-10-29 11:00 EST

Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London

NERVMinerva Neuroscience2026-08-28 12:00 EST

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

ADXNAddex Therapeutics2026-10-08 05:00 EST

Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia

TEVATeva Pharmaceutical Industries2026-09-18 20:30 EST

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

ANNXAnnexon, Inc.2026-10-28 12:01 EST

Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial

TEVATeva Pharmaceutical Industries2026-10-09 11:00 EST

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

TSHATaysha Gene Therapies2026-11-05 13:00 EST

Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12

CGTXCognition Therapeutics2026-11-02 12:30 EST

Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026

DNLIDenali Therapeutics2026-10-30 13:30 EST

Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product

ABOSAcumen Pharmaceuticals2026-10-30 11:00 EST

Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint

View all latest news

Minerva Neuroscience

CNS Drug Development Minerva Neurosciences develops therapies for central nervous system disorders. Its lead program focuses specifically on negative symptoms of schizophrenia, an area with limited approved treatment options. Roluperidone Roluperidone is an investigational oral therapy intended to improve primary negative symptoms such...

Recent company news

NERVMinerva Neuroscience2026-10-29 11:00 EST

Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London

NERVMinerva Neuroscience2026-10-28 11:00 EST

Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia

NERVMinerva Neuroscience2026-08-28 12:00 EST

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

NERVMinerva Neuroscience2026-08-07 11:00 EST

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

NERVMinerva Neuroscience2026-06-01 20:05 EST

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

Stock data

Close
2.30 USD
Market cap
221.3M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States